ROsuvastatin LOading and Clinical Outcomes Trial

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present study was to evaluate the effect of pre-procedural single high loading dose (40 mg) of rosuvastatin on the primary end-points of all cause mortality and composite of death or myocardial infarction from cardiovascular (CV) causes, target vessel revascularization (TVR), or stroke.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yuksek Ihtisas Hospital
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• statin-naive patients

• stable ischemic heart disease

• de novo lesions appropriate for PCI

Exclusion Criteria:

• current statin use

• statin allergic patients

• acute coronary syndromes

• lesions not appropriate for PCI

• refusal for participation

• statin quitting during follow- up